Results 21 to 30 of about 26,025 (223)

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Pathology and Oncology Research, 2023
Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation.
Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala   +6 more
doaj   +1 more source

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT [PDF]

, 2017
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation ...
Beelen, Dietrich, Bittenbring, Jörg, Blaise, Didier, Blok, Henric-Jan, Castagna, Luca, Chevallier, Patrice, Ciceri, Fabio, Corradini, Paolo, Eikema, Dirk-Jan, Foá, Roberto, Hallek, Michael, Hilgendorf, Inken, Koc, Yener, Kröger, Nicolaus, Moreno, Carol, Müller, Lutz Peter, Schetelig, Johannes, Selleslag, Dominik, Solano, Carlos, Theobald, Matthias, Tischer, Johanna, van Gelder, Michel, van Gorkom, Gwendolyn, van Lint, M. T.   +23 more
core   +1 more source

Venetoclax-containing regimens in acute myeloid leukemia

Therapeutic Advances in Hematology, 2021
Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML).
Ibrahim Aldoss, Vinod Pullarkat, Anthony S. Stein   +2 more
doaj   +1 more source

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Cell Death and Disease, 2022
Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing   +7 more
doaj   +1 more source

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma [PDF]

, 2017
Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.
Barbieri, Eveline, Moreno-Smith, Myrthala, Shohet, Jason, Speleman, Franki, Van Goethem, Alan, Van Maerken, Tom, Vandesompele, Jo, Vasudevan, Sanjeev A, Yigit, Nurten   +8 more
core   +3 more sources

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia

Haematologica, 2023
CD40 signaling upregulates BCL-XL and MCL-1 expression in the chronic lymphocytic leukemia (CLL) lymph node microenvironment, affording resistance to the BCL-2 inhibitor, venetoclax.
Zhenghao Chen, Gaspard Cretenet, Valeria Carnazzo, Helga Simon-Molas, Arnon P. Kater, Gerritje J. W. van der Windt, Eric Eldering   +6 more
doaj   +1 more source

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia [PDF]

, 2016
Peer ...
Eldfors, Samuli, Fløisand, Yngvar, Gjertsen, Bjorn-Tore, Heckman, Caroline Akemi, Höglund, Martin, Kallioniemi, Olli-Pekka, Kontro, Mika, Kumar, Ashwini, Majumder, Muntasir Mamun, Malani, Dishaben Rameshbhai, Parsons, Alun, Pemovska, Tea, Porkka, Kimmo Veli Kristian, Remes, Kari, Saarela, Jani Sakari, Wennerberg, Johan Krister, Yadav, Bhagwan   +16 more
core   +1 more source

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Haematologica, 2022
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly ...
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro   +24 more
doaj   +1 more source

Erythematous Macular Eruption in an Older Woman [PDF]

, 2019
A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil, McLaughlin, David, Tauro, Sudhir   +2 more
core   +2 more sources